Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30782878 | 1.00 | TAAR1 (0.60) | TAAR1ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL8276903 | 0.84 | TSHR (0.61) | ALDH1A1KMT2ALMNATSHRGAA | |
| SCHEMBL19258004 | 0.83 | ALDH1A1 (0.58) | TAAR1ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL14438274 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KMT2ALMNATSHRGAA | |
| SCHEMBL20031046 | 0.81 | TSHR (0.59) | ALDH1A1KMT2ALMNATSHRGAA | |
| SCHEMBL20031062 | 0.81 | TSHR (0.59) | ALDH1A1KMT2ALMNATSHRGAA | |
| SCHEMBL13197463 | 0.81 | ALDH1A1 (0.51) | TAAR1ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL15286987 | 0.81 | ALDH1A1 (0.56) | TAAR1ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL19821145 | 0.80 | TAAR1 (0.56) | TAAR1ALDH1A1KMT2ALMNATSHR | |
| SCHEMBL19821147 | 0.80 | TAAR1 (0.56) | TAAR1ALDH1A1KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| CN-1246319-C | Amino (thio) ether derivative | MERCK PATENT AG (DE) | 2006-03-22 | — | — | CN | disclosed |
| CN-1130180-A | Amino (thio) ether derivative | MERCK PATENT AG (DE) | 1996-09-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | TAAR1 2640/4885ALDH1A1 2070/4885KMT2A 3141/4885 |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | TAAR1 4242/4885ALDH1A1 2611/4885KMT2A 4702/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | TAAR1 3354/4885ALDH1A1 4715/4885KMT2A 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.